NNZ-2591
Phelan-McDermid Syndrome
Key Facts
About Neuren Pharmaceuticals
Neuren Pharmaceuticals is a clinical-stage biotech focused on developing first-in-class treatments for severe neurodevelopmental disorders. Its core achievement is the FDA approval and commercialization of DAYBUE® for Rett syndrome, executed through a strategic partnership with Acadia Pharmaceuticals. The company's strategy leverages a proprietary neurotrophic factor platform to advance a pipeline led by NNZ-2591 into multiple high-need orphan indications, aiming to replicate its initial success and build a sustainable neurology franchise.
View full company profileAbout Neuren Pharmaceuticals
Neuren Pharmaceuticals is a clinical-stage biotech focused on developing first-in-class treatments for severe neurodevelopmental disorders. Its core achievement is the FDA approval and commercialization of DAYBUE® for Rett syndrome, executed through a strategic partnership with Acadia Pharmaceuticals. The company's strategy leverages a proprietary neurotrophic factor platform to advance a pipeline led by NNZ-2591 into multiple high-need orphan indications, aiming to replicate its initial success and build a sustainable neurology franchise.
View full company profileAbout Neuren Pharmaceuticals
Neuren Pharmaceuticals is a clinical-stage biotech focused on developing first-in-class treatments for severe neurodevelopmental disorders. Its core achievement is the FDA approval and commercialization of DAYBUE® for Rett syndrome, executed through a strategic partnership with Acadia Pharmaceuticals. The company's strategy leverages a proprietary neurotrophic factor platform to advance a pipeline led by NNZ-2591 into multiple high-need orphan indications, aiming to replicate its initial success and build a sustainable neurology franchise.
View full company profileAbout Neuren Pharmaceuticals
Neuren Pharmaceuticals is a clinical-stage biotech focused on developing first-in-class treatments for severe neurodevelopmental disorders. Its core achievement is the FDA approval and commercialization of DAYBUE® for Rett syndrome, executed through a strategic partnership with Acadia Pharmaceuticals. The company's strategy leverages a proprietary neurotrophic factor platform to advance a pipeline led by NNZ-2591 into multiple high-need orphan indications, aiming to replicate its initial success and build a sustainable neurology franchise.
View full company profileAbout Neuren Pharmaceuticals
Neuren Pharmaceuticals is a clinical-stage biotech focused on developing first-in-class treatments for severe neurodevelopmental disorders. Its core achievement is the FDA approval and commercialization of DAYBUE® for Rett syndrome, executed through a strategic partnership with Acadia Pharmaceuticals. The company's strategy leverages a proprietary neurotrophic factor platform to advance a pipeline led by NNZ-2591 into multiple high-need orphan indications, aiming to replicate its initial success and build a sustainable neurology franchise.
View full company profileTherapeutic Areas
Other Phelan-McDermid Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| Investigational drug for Phelan-McDermid Syndrome | AMO Pharma | Clinical (Phase unspecified) |